Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.109-114, 2005 |
||
Title: Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients | ||
Author: Y., DANESHBOD ; Z., AMIRGHOFRAN ; S.Z., TABEI ; | ||
Abstract: Product of Bcl-2 gene prolongs survival of hematopoietic cells by
inhibition of programmed cell death. The aim of this study is to
examine the expression of the bcl-2 protein in a group of patients
with AML and its relation to clinical features and response to
therapy.
Slides from the bone marrow or peripheral blood of 70 patients
with AML were assessed for the expression of bcl-2 by
immunocytochemistry. The expression of myeloid and non-lineage
associated markers was detected by indirect immunofluorescence
method. Correlation between bcl-2 and markers expression and
patients characteristics was determined.
More than 20 % positivity for bcl-2 was found in 22 (31.4 %)
patients. Bcl-2 expression showed an association with M4 and M5
subtypes (p<0.01) and was correlated with clinical parameters
including WBC and platelet count, extramedullary disease and Hb
level. Bcl-2 expressing cells were significantly higher in CD15+
and CD13+ patients and lower in CD11b+ and CD33+ cases (p<0.001).
Complete remission (CR) rate was significantly lower in cases with
20 % or more bcl-2 positivity than others (24.4 % v 75.6 %). A
shorter CR duration was observed in bcl-2+ patients when compared
with bcl-2- ones (571±50 versus 850±17 days)(p=0.0001).The
expression of bcl-2 was also associated with shorter survival
(p=0.0001). Survival time for bcl-2+ patients was 831±44 days
versus 1119±17 days for bcl-2- ones. CD11b and CD33 positivity was
associated with longer survival whereas CD13 and CD15 positivity
was correlated with lower survival (p<0.007). In multivariate
analysis bcl-2 positivity was associated with poor survival.
Bcl-2 expression showed a prognostic value in our patients
indicating that even despite of some differences in treatment
regimen, immunocytochemical analysis of this marker is still a
simple and inexpensive method for evaluation of prognosis in AML
patients. Bcl-2 expression may be related to the expression of
differentiation associated markers.
|
||
Keywords: acute myelogenous leukemia, bcl-2 | ||
Year: 2005, Volume: 52, Issue: | Page From: 109, Page To: 114 | |
|
download file |
|